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Discovered over fifty years ago, autophagy is a double-edged blade. On one hand, it
regulates cellular energy sources by “cannibalization” of its own cellular components,
feeding on proteins and other unused cytoplasmic factors. On the other, it is a recycling
process that removes dangerous waste from the cytoplasm keeping the cell clean and
healthy. Failure of the autophagic machinery is translated in dysfunction of the immune
response, in aging, and in the progression of pathologies such as Parkinson disease,
diabetes, and cancer. Further investigation identified autophagy with a protective role
in specific types of cancer, whereas in other cases it can promote tumorigenesis.
Evidence shows that treatment with chemotherapeutics can upregulate autophagy in
order to maintain a stable intracellular environment promoting drug resistance and
cell survival. Leukemia, a blood derived cancer, represents one of the malignancies in
which autophagy is responsible for drug treatment failure. Inhibition of autophagy is
becoming a strategic target for leukemic stem cell (LSC) eradication. Interestingly, the
latest findings demonstrate that LSCs show higher levels of mitochondrial metabolism
compared to normal stem cells. With this review, we aim to explore the links between
autophagy and metabolism in the hematopoietic system, with special focus on primitive
LSCs.
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MAINTENANCE IN THE NICHE
Hypoxia, a Key Role in the Regulation of HSCs Quiescence
Decades of research has allowed scientists to characterize and describe the unique role of
hematopoietic stem cells (HSCs) in the lifelong homeostasis of mature blood cells. The mammalian
hematopoietic system is maintained by self-renewal of quiescent long-term (LT)-HSCs, which
subsequently can differentiate into short-term (ST)-HSCs or multipotent progenitors (MPPs). The
latter two will commit to either myeloid or lymphoid lineages exclusively. Because of their vital and
long-term function, HSCs are provided with unique survival mechanisms. In this context, their
localization in a complex endosteal niche, that is characterized by low levels of oxygen, is central
(Szade et al., 2017). Changes in the bone marrow niche, such as increased production of growth
factors and cytokines, as well as transplantation procedures and injuries, can stimulate HSCs to
proliferate and differentiate. Once recovery is restored, HSCs return to a dormant state. Despite the
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fact that hypoxia tolerance in HSCs is poorly understood, it
has been proposed to be responsible for the quiescence and
slow cell cycling of HSCs (Cipolleschi et al., 1993; Parmar
et al., 2007). Takubo et al. (2010) elucidated this mechanism
by demonstrating that hypoxia-inducible factor-1α (HIF-1α), a
transcriptional factor that plays a central role in cellular response
to oxygen levels, is stabilized by hypoxia in LT-HSCs. In HIF-1α
deficient mice, loss of LT-HSCs numbers is directly proportional
to loss of quiescence. This now raises the question: in what
ways hypoxia can assume a protective role and assure LT-HSCs
maintenance? HIF-1α and hypoxia have in fact, been linked with
the distinct metabolic phenotype of HSCs.
HIF-1α and the Regulation of HSCs
Metabolism
Metabolomic approaches indicate that LT-HSCs, when compared
to MPPs and more differentiated cells, specifically upregulate
glycolysis and represses influx of glycolytic metabolites into
mitochondria, via regulation of pyruvate dehydrogenase kinase
(PDK) activity by HIF-1α (Takubo et al., 2013; Figure 1).
Furthermore, glycolytic adenosine triphosphate (ATP)
production, commissioned by the HIF-1α/PDK regulatory
system, is necessary to maintain HSCs during cell cycle
quiescence. A recent discovery demonstrates that mitochondrial
protein mitofusin 2 (MFN2), which has roles in mitochondrial
fusion and in tying mitochondria to the endoplasmic reticulum,
is essential for the maintenance of HSCs with wide lymphoid
potential (Luchsinger et al., 2016). A different study identified
that the mitochondrial unfolded protein response (UPRmt)
is activated upon transition from quiescence to proliferation
in HSCs (Mohrin et al., 2018). Remodeling the activity of
sirtuin 7 (SIRT7), a component of the UPRmt, is translated
into reduction of quiescence, higher mitochondrial unfolded
protein stress, and insufficient self-renewal ability of HSCs.
Furthermore, SIRT7 expression is lower in more mature HSCs
whose regenerative capacity is improved following upregulation
of SIRT7 (Mohrin et al., 2015). Kim et al. (1998), using a
cationic fluorescent dye that selectively accumulates in the
mitochondria of eukaryotic cells, demonstrated that HSCs have
relatively less mitochondria when compared to proliferating
progenitors. A subsequent study showed that differentiation of
primary human HSCs (quantified by CD34 loss) is connected
with increased mitochondrial content (Piccoli et al., 2005). In
agreement with this, Simsek et al. (2010) showed that LT-HSCs
are characterized by low mitochondrial potential and utilize
cytoplasmic glycolysis for ATP production. Contrarily, cells that
need to cycle and expand do not rely on anaerobic glycolysis.
This may be because pyruvate produced during glycolysis
will generate only 2 ATPs per molecule of glucose following
anaerobic respiration (with lactate being the by-product), while
it will produce 32 ATPs per molecule of glucose upon entering
in the mitochondria to be used for oxidative phosphorylation
(OXPHOS). However, de Almeida et al. (2017) using dye-
independent methods, such as mitochondria DNA quantification
and enumeration of mitochondria nucleoids, have recently
suggested that while HSCs have high mitochondrial content
they have compromised respiratory and turnover capacity,
concluding that mitochondria perform an essential and yet
unknown function in HSCs, which may not be directly linked
with ATP production.
Stem Cell Proliferation and Maintenance,
a Key Role for Fatty Acid Oxidation
LT-HSCs glycolytic phenotype can be seen as a protective
mechanism to reduce reactive oxygen species (ROS) generation,
which would cause oxidative stress and induce differentiation
(Folmes et al., 2012). Based on this, a recent study demonstrates
that while mitochondrial complex III subunit Rieske iron
sulphur protein (RISP) in fetal HSCs is not essential for
mitochondrial membrane potential maintenance, it is crucial
for stem cell genes and multilineage potential retainment (Ansó
et al., 2017). Based on the critical role of mitochondria in
driving cell differentiation, RISP null fetal HSCs were unable to
generate an adequate number of MPPs indicating compromised
HSCs differentiation. In addition, products of the tricarboxylic
acid (TCA) cycle, such as citrate, could be exported to the
cytosol to contribute to lipid metabolism that is required
for cell growth, proliferation and differentiation (Lum et al.,
2007).
HSCs fate is dictated by their decision to undergo symmetric
or asymmetric cell division when HSCs leave quiescence.
Asymmetric division generates two daughter cells of which
one will show same features of the initiator cell, such as self-
renewal and quiescence, and the other will differentiate and
enter the circulatory system. Otherwise, symmetric division will
generate two daughter cells that will only be able to undergo cell
cycling and differentiation. Fatty acid oxidation (FAO), which
occurs in the mitochondria, also plays an important role in
HSCs maintenance. FAO metabolism prevents HSCs exhaustion
when HSCs proliferation and division are required, resulting in
asymmetric division and thus assuring self-renewal (Ito et al.,
2012). A role for peroxisome proliferator-activated receptor delta
(PPARδ), which is a member of a nuclear receptor superfamily
of transcription factors that controls nutrient sensing and FAO,
has been reported in HSCs. PPARδ deletion or pharmacological
inhibition of FAO stimulates the symmetric commitment of
HSCs leading to stem cell depletion, while PPARδ activation,
via use of an agonist, increased asymmetric cell division. In
agreement with this, a subsequent study showed that weakening
the mitochondrial phosphatase protein tyrosine phosphatase
1 (PTPMT1), drives the conversion from glycolysis and FAO
to mitochondrial aerobic metabolism, resulting in unsuccessful
hematopoiesis (Yu et al., 2013). This is linked with accumulation
of HSCs unable to differentiate due to increased entry of
quiescent stem cells into the cell cycle and a following pause at
the G1 phase.
HSCs MAINTENANCE: GLYCOLYSIS
VERSUS OXPHOS
As introduced above, HSCs maintenance is affected by a balance
between HSCs metabolic status and ROS levels. In fact, dormant
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FIGURE 1 | Overview of metabolic features contributing to HSCs maintenance and differentiation in the endosteal niche. (A) HSCs are characterized by the
expression of the surface marker CD34 and utilize anaerobic glycolysis and fatty acid oxidation (FAO) as the sources of energy. Nutrient sensor peroxisome
proliferator-activated receptor delta (PPARδ) promotes FAO, contributing to their self-renewal capacity. HIF-1α represents a fundamental feature in regulating
oxidative metabolism via regulation of pyruvate dehydrogenase kinase (PDK). (B) Transplantation procedures, cytokines and injuries can promote HSCs to proliferate
and differentiate. (C) Differentiated HSCs lose their stemness surface marker CD34 and adapt their energy source to address energy demand for proliferation.
CD34− HSCs, rely on increased oxidative metabolism that provides a higher production of ATP compared to anaerobic glycolysis. Oxidative metabolism can result in
increased production of reactive oxygen species (ROS), which can contribute to differentiation. PDH, pyruvate dehydrogenase; MFN2, mitofusin 2.
HSCs seem to rely on glycolysis to avoid a decline in HSCs
maintenance and HSCs with defective glycolysis will switch to
a mitochondrial metabolic profile with increased production
of ROS (Wang et al., 2014). ROS have been largely found
to contribute to bone marrow failure as one of the main
sources for DNA damage and genome instability (Richardson
et al., 2015), thus ROS can play a role as sensor dictating
HSCs fate. Mitochondria, which are the main source of energy
and indirectly of ROS, are considered as minor player in the
maintenance of HSCs maintenance. However, HSCs highly rely
on mitochondria when a metabolic switch is required (i.e.,
HSCs need to increase their proliferation rate). FOXO3, a
transcriptional factor that shows multiple functions associated
with longevity, is a regulator of HSCs metabolism. Loss of
FOXO3 alters mitochondria function, inducing deleterious
accumulation of ROS (Rimmele et al., 2015; Bigarella et al., 2017).
Specifically, deletion of FOXO3 in HSCs compromise DNA
repair pathway leading to DNA damage, which compromises
HSCs function. Mutation in tuberous sclerosis complex 1 (TSC1),
a negative regulator of mTOR and a key regulator for cellular
metabolism, induces levels of ROS and loss of quiescence
in HSCs (Chen et al., 2008). Additionally, mTOR activity
contributes to erythroid differentiation favoring mitochondria
activity and is also increased with aging (Luo et al., 2014; Liu
et al., 2017). Moreover, mTOR is one of the main regulators
of autophagy, a process that itself has a critical role in HSCs
biology.
AUTOPHAGY
Autophagy, from the Greek auto-self and -phagy eating, is an
evolutionally conserved process first described in yeast in 1963
by Christian de Duve (de Reuck, 1963). It is a lysosomal catabolic
process that has several functions. First of all, it has a role as a
cell cleaner by reducing the chance of cell misfunction due to
accumulation of damaged cellular components and organelles. It
is also involved in microbe’s demolition and sustains metabolism
during stressful situations, such as starvation, providing building
blocks for energy production and cellular homeostasis. The
assembly of the catabolic machinery of autophagy takes place
in the cytoplasm, in double membrane vesicles known as
autophagosomes. Numerous autophagy-related (ATG) genes are
involved in their biogenesis and function that can be organized
in three main stages (Mizushima et al., 2011). The very first
step consists in the autophagy initiation and formation of the
phagophore. Signals of cellular nutrient status are sensed by
the unc-51 like autophagy activating kinase 1 (ULK1) initiation
complex which then activates autophagy and recruits a second
complex, known as VPS34 complex, resulting in the formation
of a flat unique membrane known as phagophore (Ganley et al.,
2009; Russell et al., 2013). Phagophores will then elongate and
expand leading to autophagosomal maturation. The last step
is represented by their fusion with lysosomes where proteases
will be in charge of their content demolition (Kim et al.,
2002; Yang and Klionsky, 2009). Although, keeping LT-HSCs
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in their hypoxic niche seems to satisfy maintenance of their
“dormant” state, it may not be the only factor that contributes
to their metabolism adaptation. Lately, autophagy has been
shown to be essential in preserving the organization and the
welfare of this small cell compartment (Warr et al., 2013b;
Nguyen-McCarty and Klein, 2017). The maintenance of cell
health and prevention of stem cell aging is also vital for
hematopoiesis, and the role of autophagy in degrading damaged
cellular components and organelles may be essential in this
context. Furthermore, autophagy flux negatively correlates with
cell decline in several cell subtypes including HSCs (Revuelta and
Matheu, 2017).
Autophagy, Key Player in HSCs
Maintenance
The fact that HSCs have a slow turnover increases the chance
to reduce or dilute damaged cellular components and autophagy
might be indispensable for the necessary increase in catabolic
rate. Several studies propose that autophagy can sustain glycolytic
flux, protecting HSCs from metabolic stress and expansion
stimulus in the bone marrow, thereby reducing the chance
of HSCs exhaustion. FOXO3a, a transcriptional factor that
shows multiple functions associated with longevity, regulates
levels of autophagy in HSCs in case of metabolic stress (Warr
et al., 2013a). Specifically, FOXO3a deficient mice showed a
pronounced reduction in autophagy capacity in protecting HSCs.
FIP200, a component of the ULK1 initiation complex, has also
been associated with maintenance of HSCs (Liu et al., 2010). This
study found that mice depleted with FIP200 resulted in increased
HSC proliferation, in which mitochondrial mass was higher when
compared with HSC with no depletion. ATG7, whose role is only
associated with autophagy, regulates mitochondrial homeostasis
of HSCs, as well as ROS production and cell differentiation
(Mortensen et al., 2011). Deleting ATG7 in the hematopoietic
compartment results in the loss of normal HSCs functions and
severe myelo-proliferation, causing mice death. The authors also
show that the hematopoietic stem and progenitor cell (HSPC)
compartment exhibit accumulation of mitochondria and ROS, in
addition to an increased proliferation rate and DNA impairment.
Autophagy and HSCs Cell Cycle
Orientating HSCs to quiescence and a slow cell cycle ensure
preservation and health of long-lived stem cells. Fewer replication
cycles with minimum telomere shortening ensure that HSCs
age more slowly (Liu and Rando, 2011). Despite the fact
that cyclin D family members, including cyclins D1–D3, are
expressed at different levels in HSPCs, Cao et al. (2015)
showed that only cyclin D3 responds to nutrient stress and
identified autophagy as a driving force for cell cycle entry.
Therefore, they suggest that the lower levels of autophagy
activity observed in aged mice may be due to lower cyclin D3
levels, and thus a postponed HSCs entry into the cell cycle.
This ultimately results in a defect in self-renewal (Figure 2).
The most common way to test HSCs ability to undergo self-
renewal is represented by serial transplantation of murine
HSCs from an original donor to a recipient, whose own HSCs
were completely ablated before transplantation. Recent studies
indicate that autophagy is an essential process for self-renewal.
Ho et al. (2017), demonstrated that mice with hematopoietic-
specific deletion of the essential autophagy factor ATG12
had increased numbers of cells in the peripheral blood and
spleen. The authors then performed serial transplantation of
ATG12 deficient HSCs into recipient mice. The mice receiving
the ATG12 deficient HSCs showed dramatically impaired
engraftment and reduced number of regenerated HSCs. It has
recently been reported that ATG7 can bind p53 and modulate
TP53/p53 checkpoint in cell cycle exit in response to metabolic
stress (Lee et al., 2012). Here authors showed that starved
murine fibroblasts lacking ATG7 fail to undergo cell cycle
arrest.
Mitophagy Controls Oxidative Stress in
HSCs
It is likely that to maintain latency in HSCs, it is fundamental
to have low mitochondrial activity. A phenomenon known
as mitophagy is the only known process for mitochondrial
clearance, and this function has been demonstrated to control
levels of oxidative stress. One of the key regulators of mitophagy
is PTEN-induced putative kinase 1 (Pink1) that interacts
with the outer mitochondrial membrane and with Parkin, a
E3 ubiquitin ligase, guiding mitochondria to autophagosomal
degradation (Michiorri et al., 2010; Baudot et al., 2015).
In their study Jin et al. (2018) reported that ATAD3A is
a major regulator of mitophagy. During mitophagy in the
hematopoietic system, ATAD3A functions as a bridge between
the translocase of the outer membrane complex and the
translocase of the inner membrane complex to facilitate the
import of Pink1 into mitochondria. Deletion of ATAD3A
results in enhanced mitophagy with mitochondria depletion
and blockage in differentiation, restoring HSCs pool. Another
study showed that PPAR–FAO pathway mediates clearance
of damaged mitochondria, an important process in the self-
renewing population expansion of Tie2+ HSCs in mice (Ito
et al., 2016). Tie2, a receptor tyrosine kinase, expression on
HSCs is a marker of quiescence (Iwama et al., 1993; Arai
et al., 2004). Additionally, ATG5 and ATG7 have been shown
to regulate mitophagy and oxidative stress (Zhang et al., 2009).
A robust increase in mitochondrial mass is detected in mice
with conditional depletion of ATG5 or ATG7. This is translated
in increased production of ROS and higher DNA damage in
ATG7 deficient cells than that of their wild-type counterparts.
Authors therefore highlight mitophagy as a critical mechanism
for normal HSPC function. Furthermore, it has been reported
that mice deficient in ULK1 have compromised mitochondrial
clearance during the stages of erythrocyte maturation (Kundu
et al., 2008). As previously mentioned, ROS have a major role
in HSCs decline. Since mitochondria are the main source for
ROS, mitophagy might also represent a crucial regulator for HSCs
aging. Reducing oxidative stress via mitochondria degradation
might therefore prevent HSCs exhaustion and immature aging,
although further investigation to address this hypothesis is
needed.
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FIGURE 2 | Schematic view of the main features involved in the autophagy promotion in HSCs. HSCs are characterized with high levels of autophagy. (A) Slow cell
cycle is essential to ensure maintenance of HSCs. Cyclins are a family of proteins that control the progression of cells through the cell cycle. Cyclin D3, a member of
the cyclin D family involved in the G1 phase of the cell cycle, is a nutrient stress sensor, promoting autophagy as a fuel source for cell cycle entry. ATG7 and ATG5
have been linked with mitophagy induction in HSCs. (B) ATG7 binds p53/TP53, an S phase checkpoint control that senses nutrient stress, modulating cell cycle exit.
(C) ATG12 has also been linked with HSCs maintenance. (D) FOXO3a reduces HSCs exhaustions via regulation of autophagy. (E) Members of the ULK1 initiation
complex, such as ULK1 and FIP200, have been linked with mitophagy in HSCs.
LSCs AND THE ORIGIN OF MYELOID
AND LYMPHOID LEUKEMIA
The ground-breaking discovery of the HSCs niche was made
by Schofield (1978). Since then, significant advances have
been made in describing what orchestrates HSCs maintenance.
Mutagenesis or epigenetic changes in HSCs, together with
fluctuations in the bone marrow microenvironment, are
important events to cause blood malignancies as leukemia.
Based on functional and immunophenotypic investigation of
various subtype of cells, the existence of cancer stem cells
(CSCs) was firstly described in the hematopoietic system and
it is proposed that leukemia is a stem cell disorder, initiated
by as little as a single leukemic stem cell (LSC). These cells
can originate either from rare transformed HSCs or from more
abundant and more differentiated progenitor cells. The origin
of LSCs can vary with the stage of the disease, whether the
leukemia is chronic or acute, its immunophenotype, myeloid
or lymphoid, and the nature of the transforming event. HSCs
are equipped with intrinsic self-renewal activity that persists
for the whole life of an individual. In this context, HSCs
have much higher chance to accumulate mutations than less
primitive cells, which are not as long lived. LSCs initiation
and maintenance is based on enhanced self-renewal activity
(Argiropoulos and Humphries, 2007; Wang et al., 2010). In the
case of leukemic cells, they could potentially originate from
more restricted progenitors by acquiring mutations that allow
them to self-renew, or from HSCs that accumulate genetic
and epigenetic changes that down-regulate cell death and
increase their self-renewal capability. To fully understand the vast
heterogeneity of the disease we will briefly introduce each type of
leukemia.
Origin and Aberrations in AML
Acute myeloid leukemia (AML) is the most common leukemia
in adults and the origin of AML has been thoroughly
investigated. The t(8,21) and the t(15,17) are the most frequent
chromosomal abnormalities associated with AML (Downing
et al., 2000). Nucleophosmin (NPM1), CCAAT/enhancer-
binding protein alpha (CEBPA), FMS like tyrosine kinase 3-
internal tandem duplication (FLT3-ITD) and proto-oncogene
receptor tyrosine kinase (KIT) are the most common mutations
in AML patients, dictating the development of the leukemia
and rearranging them into different prognostic groups (Welch
et al., 2012; Yohe, 2015; Figure 3). Mutations such as
isocitrate dehydrogenase (IDH) that occurs in early stages
of the disease, lead to pre-leukemia development of AML
(founder mutation) (Thomas and Majeti, 2017). Later in
the disease progression, acquisition of driver mutations such
as FLT3-ITD can cause the full-blown disease phenotype
and further tertiary mutations can contribute to disease
heterogeneity. In 1994 it was shown that leukemic cells
possessing the CD34+CD38− cell-surface markers were able
to initiate leukemia in severe combined immunodeficiency
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FIGURE 3 | A compilation of factors involved in leukemic transformation. The figure represents a compilation of the various influences involved in the leukemic
initiation process that characterizes each type of leukemia. Mutations and epigenetics changes, such as a distinct metabolic profile that drives leukemic stem cells
(LSCs) expansion, autophagy which contributes to fuel LSCs energy demand and hypoxic environment, seem to be some of the main inducers of changes in HSCs
and initiate leukemia. With the help of extended research in the field, we might be able to study and or perturb these influences for a better understanding of each
type of leukemia and ultimately better-tailored therapeutics. List of abbreviations; CML, chronic myeloid leukemia; AML, acute myeloid leukemia; CLL, chronic
lymphocytic leukemia; B-CLL, B cell CLL like phenotype; ALL, acute lymphoblastic leukemia; Ph-like ALL, Philadelphia chromosome-like ALL; Ph+, Philadelphia
positive; NPM1, Nucleophosmin; FLT3-ITD, like tyrosine kinase 3-internal tandem duplication; KIT, proto-oncogene receptor tyrosine kinase; IKZF1, IKAROS family
zinc finger 1; E2A, transcription factor 3; EBF1, early B-cell factor 1; PAX5, paired box 5; IGHV, non-mutated immunoglobulin heavy chain variable genes; NOTCH1,
Notch homolog 1, translocation-associated; SF3B1, splicing factor 3B subunit 1; BIRC3, baculoviral IAP Repeat Containing 3. CD34 and CD38 are markers of
hematopoietic stem and progenitor cells.
(SCID) mice, while CD34+ or certain CD34+CD38+ expressing
cells were unable to do so. Moreover, limiting dilution
assays showed that leukemic-initiating cells (LICs) were a
small fraction of the entire disease, representing roughly 1
in 250,000 leukemic cells (Lapidot et al., 1994). Bonnet and
Dick, the pioneers of developing and refining transplantation
techniques of human cells into recipient mice, demonstrated
that only CD34+CD38− fractions of cell types isolated from
AML patients could engraft in recipient mice (Kamel-Reid
et al., 1989; Lapidot et al., 1994). This observation has
been further supported by the finding of Blair et al. (1997)
indicating that LICs from human AML samples were also
Thy-1−. However, Taussig et al. (2010) indicate that LICs
from AML patients with mutated NPM1 reside in the CD34−
fraction.
Origin and Aberrations in CML
Almost 100% of chronic myeloid leukemia (CML) patients are
positive for the Philadelphia (Ph) chromosome, a shortened
chromosome 22 that arises from a reciprocal translocation
t(9q34,22q11) (Rowley, 1973; Raskind and Fialkow, 1987). The
Ph chromosome is the hallmark of the disease, in which fusion
of BCR and ABL genes encode for an constitutively active
protein kinase (Daley et al., 1990; Sawyers, 1999). Since BCR-
ABL fusion can occur in myeloid, B lymphoid, erythroid and
sporadically T lymphoid cells in the majority of CML patients,
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the consensus is that the original translocation takes place in
LT-HSCs (Fialkow et al., 1977). The presence of BCR-ABL
in endothelial cells originating from CML patient, raises the
question: does the aberration take place even in more primitive
cells than LT-HSC (Gunsilius et al., 2000)? An elegant experiment
conducted by Fialkow et al. (1967, 1981) using patterns of
inactivation in X-linked genes, showed that erythrocytes and
myeloid cells in female CML patients with heterozygous X-linked
glucose-6-phosphate dehydrogenase (G6PDH) had the same
single isoenzyme type for G6PDH in contrast to normal cells,
which were heterogeneous. These results suggested that both
erythrocytes and granulocytes share a common stem cell,
demonstrating that CML is a clonal disease with a stem cell
origin. A recent study showed that while BCR-ABL expressing
progenitor cells were eliminated following imatinib treatment
in patients with a major molecular response (MMR), BCR-
ABL expressing HSCs were still detectable (Abe et al., 2009).
In chronic phase, the leukemic clone seems to be maintained
by a small number of BCR-ABL positive CD34+CD38− cells, a
population enriched for HSCs (Fialkow et al., 1977). These LSCs
differentiate normally and proliferate slowly like normal HSCs.
However, as these cells progress into intermediate phases of
lineage restriction, their progeny proliferate losing their primitive
marker CD34. By analyzing different subpopulation of primitive
CML cells it has been shown that an unusual autocrine IL-3-
granulocyte colony-stimulating factor mechanism can provide
a strong rational for the unusual performance of BCR-ABL
expressing stem and progenitor cells (Chang et al., 1989;
Holyoake et al., 2002). This mechanism only moderately offsets
the in vivo signals, which maintain normal HSCs quiescence
but, when active in BCR-ABL expressing LSCs, drives their
differentiation at the expense of their self- renewal. In less
primitive CML progenitors, the same mechanism has a more
potent mitogenic effect that is then quenched when the cells
progress into the final phases of differentiation.
Origin and Aberrations in ALL
Acute lymphoblastic leukemia (ALL) defines a group of blood
malignancies that frequently have chromosomal or intra-
chromosomal changes. These rearrangements can impact on
immunoglobulin or T-cell receptor genes that drive commitment
to the lymphoid lineage. What has been elusive is proving the
existence of a rare stem cell-like population that are capable
of maintaining ALL. There have been conflicting results from
studies investigating whether there is a CSC-like subpopulation
in ALL. The heterogeneity of ALL itself may be responsible
for some of these inconsistencies. Possible explanations for the
pronounced variation in response to therapy include the presence
of primitive LICs for each subtype of ALL and the different
biology of the cell of origin. While chromosomal abnormalities
are a key hallmark of ALL, on their own they are insufficient
to generate the disease. Characteristic translocations include
t(1,19), t(12,21), and t(9,22) (Mullighan et al., 2009). Cytogenetic
abnormalities and transcription profiling approaches divide ALL
into several subcategories, in which prognosis and frequency
differ significantly in different age groups (Mullighan, 2014). One
of these subcategories is Ph chromosome-like ALL (Ph-like ALL),
which gives rise to the BCR-ABL oncogene and this is one of the
most adverse abnormalities seen in ALL patients. Ph-like ALL is
the group with Ph-negative B-lineage ALL but has a transcription
profile similar to those of patients that have Ph-positive ALL (Den
Boer et al., 2009). Genetic abnormalities associated with ALL
cases are not homogeneous, and the most common mutations
associated with the Ph-like subtype are the IKAROS family zinc
finger 1 (IKZF1), paired box 5 (PAX5), early B-cell factor 1
(EBF1), and transcription factor 3 (E2A) (Mullighan et al., 2007).
Likewise, kinase-activating mutations are seen in 90% of the Ph-
like ALL. The most frequent of these include rearrangements
involving abelson murine leukemia viral oncogene homolog 1
(ABL1), Janus kinase 2 (JAK2), and FLT3 (Roberts et al., 2012).
Origin and Aberrations in CLL
Chronic lymphocytic leukemia (CLL) is defined by a very
heterogeneous clinical course. Genomic aberrations are present
in more than 80% of cases including 11q deletion (11q-), trisomy
12 (11-), 17p deletion (17p-), and 13q deletion (13q-) and
each of these is associated with a specific clinical outcome.
Inactivation or mutation of the tumor suppressor 53 (TP53)
results in a more aggressive CLL phenotype in patients with
17p- (Döhner et al., 1995). Non-mutated immunoglobulin heavy
chain variable genes (IGHV) is linked with high-risk clinical
characteristics and shorter survival (Damle et al., 1999; Hamblin
et al., 1999). Using next generation sequencing techniques has
revealed a more detailed panel of aberrations such as Notch
homolog 1, translocation-associated (NOTCH1), baculoviral IAP
Repeat Containing 3 (BIRC3) and splicing factor 3B subunit 1
(SF3B1) (Puente et al., 2011; Quesada et al., 2012). NOTCH1
and SF3B1 represent the most frequently mutated genes in CLL,
being present in the majority of patients (Wang et al., 2011).
The results of xenogeneic transplantation studies have shown that
HSCs isolated from patients with CLL firstly differentiate into
B cell progenitors and only later stimulus and rearrangements
can address them within a B-CLL-like phenotype (Kikushige
et al., 2011). While it’s not certain that these cells constitute
a type of CSC for CLL, it does seem that further genetic/or
epigenetic transformation are needed for such B cells to turn
into malignant cells. Furthermore, investigations into telomere
length and telomerase expression indicate that CLL cells with
no mutations in the immunoglobulin heavy variable (IGHV)
proliferate rapidly and undergo extensive cell division, which are
characteristic abilities of LSCs (Damle et al., 2004). In brief, these
features can lead them to leukemic transformation.
LSCs DEPENDENCY ON HYPOXIA
We have previously described how LSCs can arise from HSPCs
that reside in the hypoxic bone marrow niche. However, the
role of hypoxia in the maintenance of LSCs is still controversial,
perhaps due to point of stemness at which the hypoxia is
introduced in conflicting studies, and the length and level of
hypoxia (Deynoux et al., 2016; Huang et al., 2018). Nevertheless,
further studies are required in order to elucidate its complex
effect on LSCs maintenance and survival. Hypoxia via HIFs
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may drive disease maintenance and development through other
mechanisms such as energy metabolism, cell cycle, quiescence,
and immune function. These physiological processes can be up-
or down-regulated in cancer. In the case of AML, the existence
of an oxygen gradient in the bone marrow allows maintenance
of primary AML cells (Griessinger et al., 2014). Rouault-Pierre
et al. (2013) reported that down-regulation of HIF-2α or HIF-
1α to lesser extent, induces apoptosis and prevents leukemic
engraftment upon transplantation of human AML cells into mice.
These results suggest that HIF-2α or HIF-1α is necessary for
the maintenance of LSCs and may potentially be therapeutically
targeted for AML. On the other hand, the Velasco-Hernandez
et al. (2014) study reported that HIF-1α deletion does not affect
mouse AML maintenance, which highlights the contradictions
in the role of HIFs in AML disease. However, these differences
in effect might be dependent on the particular genetic alteration
that initiates the malignancy, revealing once more the enormous
heterogeneity of this disease. Furthermore, Vukovic et al. (2015)
developed a conditional genetic model to investigate the effect
of deletion of both HIF-1α and HIF-2α during leukemogenesis.
The authors showed that while HIF-2α had no influence on
proliferation of AML cells in a murine model, it’s important
in blocking the progression of LSCs into a malignancy. HIF-
2α deletion accelerates LSCs differentiation but does not affect
LSCs maintenance of AML (Vukovic et al., 2015). In CML,
Zhang et al. (2012) reported that deletion of HIF-1α blocks
CML progression through weakening cell cycle progression and
induction of apoptosis in LSCs. BCR-ABL oncogene in CML-
LICs, in fact, stabilizes HIF-1α to promote cell proliferation.
Whether HIF-1α has a role in the survival mechanisms of LSCs
in CLL is still unknown. In CLL, HIF-1α is stabilized even
under normoxia through down regulation of von Hippel Lindau
(VHL) protein, whose expression is compromised by HIF-1α
microRNAs (Ghosh et al., 2009). This mechanism allows the
formation of a complex (HIF-1α/p300/p-STAT3) responsible for
the expression of the vascular endothelial grow factor (VEGF)
(Ghosh et al., 2009). The authors indicate that up-regulation of
factors such as VEGF by HIF-1α plays an important role in the
microenvironment’s control of leukemic cell survival. In T-ALL,
HIF-1α stabilization induces Wnt signaling through enhanced
transcription of β-catenin (Giambra et al., 2015). Loss of HIF-1α
decreases the LSCs frequency without affecting the growth and
viability of leukemic bulk cells.
LSCs METABOLISM
Hematopoietic stem cells have a distinct energy demand to
sustain maintenance. However, demand for energy and nutrients
increase drastically upon cell division and differentiation. Cells in
order to proliferate, on top of increasing biomass and duplicate
their genome, upregulate the metabolic rates of nucleotides,
proteins and lipids. Consequently, cancer cells must adapt
their metabolism, particularly by increasing nutrient uptake, to
maintain their uninhibited proliferation (Dang, 2012). In fact,
the metabolism of cancer cells is not an indirect by-product
of proliferation but also a direct reprogramming orchestrated
by oncogenic signaling (Ward and Thompson, 2012; Pavlova
and Thompson, 2016). Investigating the metabolic phenotype
of LSCs might clarify their survival mechanism and their
persistence and progression though the development of the
disease. Understanding how they are metabolic distinct from
HSCs could help for a better characterization of each type of
leukemia.
Glucose Metabolism in LSCs
Glycolytic flux is the main feature in the metabolism of HSCs.
As a rule, HSCs are energetically dormant with active glycolysis,
until they differentiate, moving to mitochondrial respiration to
survive. Song et al. (2014, 2016) showed that bone marrow
cells isolated from AML patients with no remission have
higher expression of HIF-1α, as well as glucose transporter 1
(GLUT1) and higher expression of two of the main controlling
stages of the glycolytic flux, hexokinase 2 (HK2) and lactate
dehydrogenase (LDH) compared to patients with complete or
partial remission and healthy donors. Bhanot et al. (2015) using
metabolomics approaches demonstrated that UDP-P-Glucose,
which is a glycogenic precursor of glucose, is increased in
AML regardless of low levels of glycogen. Likewise, changes
in glucose metabolism have been linked with clinical outcome
and therapeutic resistance. Herst et al. (2011) showed that high
glycolytic primary blast AML are resistant to treatment. They
indicate that myeloblast glycolytic rate could be an effective
and easily employed method to determine the pre-treatment
prognosis of AML. This conclusion is also supported by the
results of a separate study conducted in AML patients by Chen
et al. (2014). Unfortunately, recent studies are not enough to
profile the glycolytic phenotype of LSCs and further studies are
required. In support of the above results, a study conducted
in mice demonstrated that deletion of lactate dehydrogenase A
(LDHA) and of pyruvate kinase and muscle 2 (PKM2), two
enzymes that regulates last steps of glycolysis, reduced the chance
to induce leukemia (Wang et al., 2014). Finally, CML leukocytes
have higher aerobic glycolytic rates when compared to normal
and CLL leukocytes (Beck and Valentine, 1953).
Glutamine Metabolism in LSCs
An alternative source of energy is glutaminolysis, in other words
the metabolism of glutamine, the most abundant amino acid in
circulating blood. How tumor cells regulate the balance between
glycolysis and oxidative metabolism to meet their energy need
is not fully understood. While it’s been long known that the
Warburg shift is a notable hallmark of proliferating cancer cells,
they have an intact TCA cycle that becomes progressively more
reliant on glutamine metabolism when compared to normal cells.
As well as use for ATP generation, the cancer cells can use
TCA cycle intermediates as precursors for biosynthetic pathways
and glutamine anaplerosis can help sustain this. Furthermore,
glutamine is also required for protection against antioxidants
by increasing glutathione (GSH) levels that in turn neutralize
ROS. In a recent study, Gallipoli et al. (2018), exploiting CRISPR-
Cas9 screen, identified that glutaminase (GLS), the first enzyme
in glutamine metabolism, is synthetically lethal when combined
with FLT3-tyrosine kinase inhibitor (TKI) treatment. Here the
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authors combined complementary metabolomics with a CRISPR
screen to show that glutamine metabolism, through its ability
to support both the TCA cycle and GSH synthesis, becomes a
metabolic dependency of FLT3-IDT AML, specifically unmasked
by FLT3-TKI treatment. Knoechel and Aster (2015) recently
showed that signal from the PI3K-AKT pathway shifts NOTCH-
dependent T-ALL cells from glutamine metabolism to aerobic
glycolysis. Using murine models and xenograft transplantation
model of primary human T-ALL, the authors showed that T-ALL
cells with activating mutations of NOTCH1 use glutamine as the
main substrate of anaplerotic reactions that feed the TCA cycle.
Fatty Acid Metabolism in Leukemia
As discussed in the previous paragraph, LSCs may have a high
demand for glutamine to feed oxidative metabolism. Adipose
tissue represents one of the major sources of glutamine in
cells. The high amount of energy required from LSCs can
be satisfied by using fatty acid as a fuel source. Additionally,
adipocytes have a well establish role in the LSCs energy demand.
Adipocytes can store energy as triglycerides, which during
lipolysis can be catabolized into glycerol and free fatty acids
(FFA). Thus, adipocytes may deliver FFA to cancer cells, to help
meet their demands for energy and lipid synthesis. A recent
study demonstrated that adipocytes provide FFA as fuel source
to leukemia cells (Ye et al., 2016). Using a mouse model of
blast-crisis CML, Ye et al. interestingly found that LSCs have
a niche in gonadal adipose tissue (GAT). The authors used
limiting-dilution transplantation assays to show that these GAT-
resident LSCs gave rise to leukemia with a frequency similar
to that of bone-marrow-derived LSCs. Also, the GAT-associated
LSCs have high expression of the fatty acid transporter CD36.
Gene expression analysis showed LSCs have a pro-inflammatory
phenotype that increases lipolysis that fuels the LSCs’ high levels
of FAO when compared to their more differentiated progeny or
normal HSCs. These features are responsible for LSC quiescence
and resistance to chemotherapy. A previous study examining
primary human samples of AML identified in the CD34+ LSCs,
a subpopulation expressing CD36, and this CD36+ phenotype
was been linked with poor prognosis (Perea et al., 2005). In these
cases, the CD36+ LSCs also displayed an increase in uptake of
FFAs and their subsequent oxidation, suggesting that CD36 can
regulate LSCs metabolism in at least a subset of human myeloid
leukemia. Tucci et al. (2014) reported that ALL cells stimulate
adipocyte lipolysis and use the resulting FFAs to supplement
de novo lipogenesis and proliferation. In a separate study is
shown that CLL cells, in contrast with normal B-lymphocytes,
are able to catabolize lipids in order to use FFAs for oxidative
respiration (Rozovski et al., 2015). FFAs can also bind the nuclear
receptor peroxisome proliferator activated receptor α (PPARα).
The interaction between FFAs and PPARα generates a complex
that, similar to a transcription factor, activates the transcription of
enzymes necessary for OXPHOS (Kersten, 2014). Adipose tissue
can also be a protective compartment for LSCs during stressful
condition such as drug treatment. Ehsanipour et al. (2013)
report that adipocytes protect leukemia cells from L-asparaginase
treatment by secreting glutamine. This is particularly relevant
when considering that L-asparaginase is used in ALL treatment
due to leukemic lymphoblasts being highly sensitive to the
depletion of exogenous asparagine and glutamine (Oettgen et al.,
1967; Kitoh et al., 1990).
Mitochondrial Metabolism and LSCs
LSCs are resilient cells and able to exploit multiple metabolic
pathways in order to survive. In fact, LSCs can, in addition
to glucose, utilize fatty acids and amino acids such as
glutamine in order to provide precursors of the TCA cycle
to sustain mitochondrial metabolism in LSCs. Most CSCs
that are dependent on OXPHOS generally upregulate this
energy source. For this reason, CSCs can be sensitive to
mitochondrial inhibition. IDH mutated AML-LSCs acquire
increased enzymatic function generating R-2-hydroxyglutarate
(R2HG) from α-ketoglutarate (α-KG), as opposed to non-
mutated IDH, which catalyzes the conversion of isocitrate
to α-KG. The resulting accumulation of the onco-metabolite
R2HG inhibits the α-KG dependent ten-eleven translocation
(TET) protein family leading to DNA demethylation which
contributes to tumorigenesis (Dang et al., 2009). Furthermore,
cytarabine resistant AML cells enriched in quiescent LSCs,
have increased levels of mitochondrial mass, hold functional
mitochondria, which is translated into increased OXPHOS
levels with subsequent peak in ROS. Interestingly, even though
cytarabine wasn’t effective, residual cells displayed an increased
expression of OXPHOS genes together with an augmentation
in FAO and upregulation of CD36 that can be predictive for
treatment response in patients with AML (Farge et al., 2017).
In a different study it was shown that even though AML cells
have higher levels of mitochondrial mass compared to normal,
they still have lower respiratory chain complex activity and lower
spare respiration (Sriskanthadevan et al., 2015). Interestingly,
Marlein et al. (2017) recently demonstrated that NADPH oxidase
2 (NOX2) generates superoxide that stimulates bone marrow
stromal cells to transfer mitochondria to AML blast cells through
AML-derived tunneling nanotubes. CLL patients also display
an increased metabolic oxidative profile, which is linked to
alterations in their lymphoid compartment (Jitschin et al., 2014).
In this study, CLL cells were found to adapt to intrinsic oxidative
stress by increasing levels of the stress-responsive heme-
oxygenase 1 (HO-1). The results of this study implicate that HO-
1, beyond its function as an antioxidant, has additional roles in
promoting mitochondrial biogenesis and reducing the high levels
of ROS present in CLL cells. A study conducted in quiescent CLL-
LSCs exposed to three different stromal cell lines demonstrate
that OXPHOS was significantly higher when compared to CLL
cells cultured alone. Here the authors co-cultured 28 CLL
patient-derived cells with bone marrow derived natural killer
cells, M2-10B4 fibroblasts or HS-5 stromal cells, This study,
highlights the importance of considering cell-cell interactions
(Vangapandu et al., 2017). Cai et al. (2016) reported that exposure
of T-ALL cells to mesenchymal stem cells (MSCs) lowered their
mitochondrial ROS levels and promoted a Warburg-like shift that
is characterized by an increase in glucose uptake and production
of lactate with associated reduction in ATP production and
mitochondrial membrane potential. In addition, T-ALL cells co-
cultured with MSCs have altered mitochondrial morphology
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due to the extracellular signals and mediate phosphorylation
of the pro-fission factor, dynamin-related protein 1 (Drp1) at
residue S616. Supporting this was the observation that expression
of S616-phosphorylated Drp1 recapitulates mitochondrial ROS
levels, the mitochondrial dynamics, metabolic switching and
chemo-resistance observed in T-ALL cells co-cultured with
MSCs. A study conducted in primary lymphocytes and CD34+
progenitors from ALL patients indicates that since the inhibitor
of mitochondrial translation, tigecycline is able to sensitize them
to increased apoptosis, ALL might have higher levels of oxidative
metabolism (Fu et al., 2017). Interestingly, T-ALL with higher
expression of Golgi-localization of oxysterol binding protein-
related protein 4L (ORP4L) are characterized by higher levels
of OXPHOS compared to normal T-lymphocytes (Zhong et al.,
2016). Since higher ORP4L is associated with higher OXPHOS
rate and it is upregulated in 80% of CML cases, CML cells are
thought to have higher levels of oxidative metabolism compared
to their normal counterparts (Henriques Silva et al., 2003). This
was further investigated by Kuntz et al. (2017). Performing
metabolic analyses on both stem cell-enriched CD34+CD38−
and CD34+ and differentiated CD34− cells derived from patients
with CML, the authors demonstrated that most primitive LSCs
have higher mitochondrial activity than more differentiated LSCs
and normal CD34+CD38− cells. Importantly, they show that
primitive CML cells are reliant on higher rates of oxidative
metabolism for their survival.
AUTOPHAGY IN LSCs
In the last few decades the hypothesis that LSCs, as many other
CSCs, have a high-energy demand has been supported by the
results of a large number of studies. High rates of metabolism also
correspond to high levels of cellular stress and this can damage
cellular components. In this scenario, LSCs take advantage of a
survival “sustainer” process, autophagy by using it as building
block provider to address their metabolic requirements. As well as
this, autophagy contributes in keeping cells healthy by reducing
oxidative stress. Watson et al. (2015) indicated that human
and mouse HSPCs exhibited lower mitochondrial stress and
increased mitochondrial clearance due to increased autophagy
when compared to more differentiated cells. Interestingly, they
showed that ATG genes are in chromosomal regions that in AML
are frequently deleted. Mice with ATG7 and ATG5 deficiency in
the HSPCs compartment developed an early leukemic phenotype
that compromised animals, leading to death. Importantly,
deleting autophagy in both alleles in mixed lineage leukemia-
eleven nineteen (MLL–ENL) model of AML enhanced glycolysis
and proliferation in vitro and caused a more hostile leukemia
in vivo. Since loss of ATG genes have also been identified
in other malignancies, different studies have indicated that
reduction in autophagy flux represents a “plus” for tumorigenesis.
However, a recent study conducted in human CD34+ AML
cells demonstrated that low risk AML have enhanced autophagy
while intermediate risk AML is associated with limited autophagy
flux (Folkerts et al., 2017). To further characterize autophagy,
CD34+ AML cells were distributed into ROS-low and ROS-
high sub-fractions. AML CD34+ ROS-low cells exhibited higher
basal autophagy and decreased survival following treatment
with hydroxychloroquine (HCQ), an inhibitor of lysosomal
fusion during autophagy, when compared with ROS-high cells.
Furthermore, knockdown of ATG5 reduced maintenance of
AML CD34+ cells in NSG mice. Karvela et al. (2016) provided
further understanding of how autophagy inhibition affects energy
metabolism of CML cells. Loss of ATG7 impaired glycolysis
and induced a distinctive mitochondrial metabolism profile, and
the subsequent induction of ROS encouraged differentiation of
CD34+ CML cells in the erythroid lineage. Further investigations
are still required to understand the metabolic profile of LSCs,
which will also provide additional tools to elucidate the role of
autophagy in sustaining leukemic metabolism.
Mitophagy and LSCs
As described previously, mitochondrial metabolism is one
of the main sources of energy for LSCs. To assure that
oxidative metabolism can meet LSCs energetic demand, their
mitochondria need to be conformed to meet this. We have
previously indicated mitophagy as the mechanism that removes
injured mitochondria and, in this context a high demand
for mitophagy will probably assure the replenishment of
functioning mitochondria. However, this still remains to be
investigated in detail. One of the few studies conducted in
leukemia regarding mitophagy is a recent study in AML
(Pei et al., 2018). The authors indicate that primitive AML-
LSCs have higher expression of the mitochondrial dynamics
regulator F1S1 compared to non-LSCs. Using valinomycin to
stress mitochondria, they show that AML-LSCs overexpressing
FIS1 have higher levels of mitophagy than non-LSCs. Loss
of FIS1 in AML-LSCs impairs mitophagy, leading to myeloid
differentiation, block in cell cycle and restricted LSC self-renewal
ability.
Autophagy in the Initiation of Leukemia
Understanding what are the main features in the initiation of
leukemia is still of high importance. Remodeling of autophagy
function has been largely investigated in the transformation
of HSCs to LSCs. Auberger and Puissant (2017) have recently
proposed a detailed analysis of autophagy’s primary participation
in leukemogenesis (Auberger and Puissant, 2017). In the case of
AML, several studies have demonstrated that autophagy genes
are down regulated in AML cells (Brigger et al., 2013, 2014;
Walter et al., 2009). A recent study by Visconte et al. (2017),
conducting sequencing of the entire exome in patients with
different type of myeloproliferative disorder including AML,
found that expression of most relevant autophagy genes is
compromised in 14% of patients. In accordance with this,
two different studies have elucidated the effect of disrupted
autophagy in AML initiation and progression. Mortensen
et al. (2011) demonstrated that loss of the ATG7 gene in
the mice hematopoietic niche enhanced the development of
a myeloproliferative disorder. Based on that, Watson et al.
(2015) demonstrated that deletion of ATG5 impairs autophagy,
which results in developing a myeloproliferative disease in
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the animals. Specifically, using a mixed lineage leukemia-
eleven nineteen leukemia (MLL-ENL) AML mouse model the
authors demonstrated that loss of ATG5 contributes to decreased
glycolytic flux enhancing disease progression. Interestingly,
they indicate that heterozygotes loss of ATG5 increased the
progression of the disease while deletion in both alleles resulted
premature death of mice prior to developing malignancy.
Differently from AML, autophagy genes are upregulated in
CML and loss of autophagy in CD34+ CML cells results in
compromised initiation of leukemia (Rothe et al., 2014; Karvela
et al., 2016). A high-energy demand is also required for leukemia
expansion. Ianniciello et al. (2017) reported that primary CD34+
LSCs leaving hypoxic environment require metabolic adaptation
to repopulate as well as for disease expansion. In the lymphoid
counterpart, mRNA analysis showed that patients with CLL
show increased expression of BECLIN1 and ATG5 genes than
healthy controls (Kong et al., 2018). Based on these studies,
autophagy seems to dictate LSC fate depending on the stage of the
transformation, the type of leukemia and the presence of multiple
mutations that can affect the progress in the disease.
Autophagy in LSCs Drug’ Resistance
Several studies have shown that LSCs escape from drug treatment
by upregulating autophagy. TKIs, the front-line treatment of
CML, inhibit the oncogenic BCR-ABL tyrosine kinase activity
and this induces autophagic flux (Bellodi et al., 2009; Helgason
et al., 2013; Baquero et al., 2018). Arsenic trioxide is an alternative
way to remove BCR-ABL, which requires induction of the
cathepsin B, a lysosomal protease (Puissant et al., 2010; Goussetis
et al., 2012). Interestingly, CML LSCs balance autophagy between
a survival and apoptotic function. Autophagy is induced for
BCR-ABL degradation upon TKIs treatment and at the same
time promotes leukemic cell recovery following cessation of
treatment (Crowley et al., 2013). Additionally, Helgason et al.
(2011) highlighted autophagy inhibition with TKIs treatment as
a strategic approach to eradicate LSCs. While current treatment
for AML is based on combining anthracyclines with cytarabine,
use of m-TOR inhibitors has been investigated. The results of
these studies indicated that treatment with inhibitors of m-TOR
increases protective autophagy flux in AML cells (Altman et al.,
2014; Chen et al., 2017). A different approach investigated in
AML is to combine conventional chemotherapy with statins,
which act by restricting the last step of cholesterol synthesis
(Hartwell et al., 2013). However, statins induce autophagy, which
reduces the effect of treatment in targeting LSCs. A different
approach tested for AML uses a recombinant arginase to deplete
arginine levels in AML patients (Tanios et al., 2013). This is
based on the observation that AML blast cells are dependent
on income of arginine for their survival. While the effect of
targeting arginine was promising in AML blasts, cytoprotective
autophagy was increased. The same scenario has been indicated
when the disease affects the lymphoid compartment. In T-ALL,
approaches using inhibitors of NOTCH1 are used to weaken
glutamine metabolism. However, NOTCH inhibitors act as a
double edge sword: the effect on glutaminolysis is null since
NOTCH inhibitors induce autophagy, which contributes to
T-ALL metabolism (Herranz et al., 2015). Glucocorticoids are
also used in the treatment for T-ALL (Jiang et al., 2015).
Unfortunately, finding a cure for this disease seems to constantly
run in to the same issues. Glucocorticoid effect on repressing
m-TOR is translated in increased autophagy, which contributes
to resistance to treatment. In the case of B-ALL, bortezomib, a
proteasomal inhibitor has been indicated to increase cytotoxicity
(Murata et al., 2009). However, to compensate for the loss
of proteasomal activity and re-establish protein homeostasis
following bortezomib treatment, autophagy is upregulated as a
rescue mechanism (Milan et al., 2015; Wang et al., 2015).
CONCLUSION
Autophagy is indeed an important physiological process.
However, what seems the answer in certain circumstances
can be the problem in others. While HSCs use autophagy to
protect themselves, it can also be involved in their malignant
transformation. Importantly, LSCs upregulate autophagy
potentially to provide building blocks/energy in stressful
conditions, such as drug treatment. The relevance of combining
current treatment with autophagy inhibition in LSCs have come
to of a phase II clinical trial. The name of the study is CHOICES
(CHlOroquine and Imatinib Combination to Eliminate Stem
cells) and combines first line treatment for CML patients with
HCQ. However, HCQ is a non-specific autophagy inhibitor and
high doses are required to target autophagy in patients that
might not be achievable, thus there is a need to develop more
specific autophagy inhibitors to target autophagy in patients.
ULK1 and VPS34 inhibitors have been established and in vitro
results are promising (Dowdle et al., 2014; Egan et al., 2015;
Petherick et al., 2015; Baquero et al., 2018). However, further
analysis and in vivo studies using suitable robust pre-clinical
models are still necessary to validate their ability to target
autophagy in cancer patients and specifically in the context of
leukemia.
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